Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

Phase 2

Terminated

Conditions: Idiopathic Membranous Nephropathy

Interventions: Drug: LNP023
Drug: Rituximab

First Posted Date: 2019-11-06

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT04154787

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: MBG453
Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2019-11-04

Last Posted Date: 2025-04-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT04150029

Locations: 🇺🇸
25Uni of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸
Uni Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States

and more 10 locations

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Non-alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis

Interventions: Drug: LYS006
Drug: Tropifexor

First Posted Date: 2019-11-01

Last Posted Date: 2023-08-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT04147195

Locations: 🇩🇪
Novartis Investigative Site, Essen, Nordrhine Westphalia, Germany

Heart Failure IDentification in a High Risk Cardiovascular OutpatiEnt Population (HIDE)

Not Applicable

Completed

Conditions: Heart Failure

Interventions: Diagnostic Test: NYHA assessment
Procedure: Serum NT-proBNP concentration
Diagnostic Test: Transthoracic Ecocardiogram

First Posted Date: 2019-10-30

Last Posted Date: 2022-03-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 317

Registration Number: NCT04143919

Locations: 🇬🇹
Novartis Investigative Site, Guatemala city, Guatemala

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Capmatinib
Biological: Pembrolizumab

First Posted Date: 2019-10-25

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT04139317

Locations: 🇹🇭
Novartis Investigative Site, Bangkok, Thailand

Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Other: Placebo
Drug: CFZ533

First Posted Date: 2019-10-16

Last Posted Date: 2025-04-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT04129528

Locations: 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom

A Study of WVT078 in Patients With Multiple Myeloma (MM)

Phase 1

Terminated

Conditions: Multiple Myeloma (MM)

Interventions: Biological: WVT078
Drug: WHG626

First Posted Date: 2019-10-10

Last Posted Date: 2025-01-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT04123418

Locations: 🇺🇸
Emory University School of Medicine-Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab

Phase 3

Withdrawn

Conditions: Migraine

Interventions: Drug: erenumab 70mg/mL

First Posted Date: 2019-10-03

Last Posted Date: 2020-06-01

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04114630

Locations: 🇪🇸
Novartis Investigatice Site, Madrid, Spain
🇪🇸
Novartis Investigational Site, Valencia, Comunidad Valenciana, Spain
🇪🇸
Novartis Investigative Site, Madrid, Spain

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064

First Posted Date: 2019-09-30

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 229

Registration Number: NCT04109313

Locations: 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Diffuse Large B Cell Lymphoma
Lymphoma, T-Cell
Mesothelioma, Malignant
Prostatic Neoplasms, Castration-Resistant
Endometrial Cancer
Ovarian Clear Cell Carcinoma
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Tulmimetostat
Drug: Enzalutamide

First Posted Date: 2019-09-26

Last Posted Date: 2025-05-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 275

Registration Number: NCT04104776

Locations: 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States

and more 57 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy